Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of Serum ELABELA in Early Diagnosis of Sepsis-Associated Acute Kidney Injury

NCT06001294 is registered in ClinicalTrials.gov with Xiangcheng Zhang as lead sponsor.

NCT NCT06001294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of Serum ELABELA in Early Diagnosis of Sepsis-Associated Acute Kidney Injury
Lead sponsor
Xiangcheng Zhang
Phase
Observational
Overall status
Unknown status
Start date
July 3, 2022
Completion date
December 31, 2023
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, sepsis, septic shock